Real-world treatment patterns of patients with major depressive disorder treated with Auvelity in the United States.
Aims: Major depressive disorder (MDD) is a prevalent, chronic disorder. Auvelity (dextromethorphan-bupropion) is a novel, oral N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved (August 2022) by the FDA for treating MDD in adults. This is the first analysis on real...
| Publicado en: | Journal of Medical Economics Vol. 27; no. 1; pp. 1003 - 1011 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Taylor & Francis Ltd
Jan-Dec2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |